RS Investment Management’s Pacira BioSciences PCRX Stock Holding History

RS Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-610,987	Closed	-$54.3M	–	372
2015 Q1	$54.3M	Buy	610,987 +16,664	+3%	+$1.69M	0.48%	69
2014 Q4	$52.7M	Sell	594,323 -94,870	-14%	-$8.97M	0.47%	75
2014 Q3	$66.8M	Buy	689,193 +405,160	+143%	+$39.4M	0.62%	51
2014 Q2	$26.1M	Sell	284,033 -983	-0.3%	-$74.9K	0.22%	148
2014 Q1	$19.9M	Sell	285,016 -43,900	-13%	-$2.99M	0.12%	189
2013 Q4	$18.9M	Sell	328,916 -109,800	-25%	-$5.77M	0.12%	188
2013 Q3	$21.1M	Sell	438,716 -52,500	-11%	-$1.91M	0.14%	167
2013 Q2	$14.2M	Buy	+491,216	New	+$14.2M	0.1%	186

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RS Investment Management's PCRX Position: Q2 2015 in Review

RS Investment Management sold out of Pacira BioSciences (PCRX) in Q2 2015, closing a stake of 610,987 shares — an estimated $54.3M sold.

RS Investment Management first reported a position in PCRX in Q2 2013 and held it in 8 quarters. The position peaked at $66.8M in Q3 2014. 187 funds tracked by Wall St. Rank hold PCRX as of Q2 2015.

RS Investment Management reported no remaining Pacira BioSciences position as of Q2 2015 after selling out during the quarter.
RS Investment Management sold 610,987 Pacira BioSciences shares in Q2 2015, an estimated $54.3M.
RS Investment Management first reported a position in Pacira BioSciences in Q2 2013 and held it in 8 quarters.
RS Investment Management's Pacira BioSciences position peaked at $66.8M in Q3 2014.
187 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2015.

Based on RS Investment Management's 13F filing for Q2 2015, filed 13 Aug 2015.